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Abstract 1 
 2 
Background: Individuals with an impairment make up over 15% of the world’s population, 3 
many of whom can benefit greatly from participation in sport. The provision of medical 4 
services in disability sport is a challenging area with a lack of scientific evidence. Given the 5 
positive impact that sport can have on the people with an impairment, it is vital that 6 
measures are taken to better understand the medical issues posed by disability sport. It is 7 
well established that medications and supplements are over-used in sport, particularly 8 
within professional football, but there is no current evidence on medication or supplement 9 
use in elite disability football. 10 
 11 
Objective: To examine and describe the use of medication and supplements in disability 12 
football, prior to and during international tournaments, and to identify the profile of 13 
substances used by category. 14 
 15 
Design: Prospective, descriptive, cohort study. 16 
 17 
Setting: International Blind Sport Association (IBSA) Football World Cup 2015 and the 18 
International Federation of Cerebral Palsy Football (IFCPF) World Cup 2015. 19 
 20 
Participants: Two hundred and forty-two elite level disability footballers, classified with B1 21 
visual impairment or cerebral palsy. 22 
 23 
Methods: Team clinicians were asked to document all medication and supplements taken in 24 
the 48 hours prior to each match. 25 
 26 
Results: This study recorded the use of 1648 substances in 242 players, with more than half 27 
(53.1%) classified as supplements. There was an overall rate of 1.26 substances used per 28 
player per match and a medication use rate of 0.59 medications per player per match. 29 
Seventy percent (170/242) of players reported using at least one substance per tournament, 30 
with 57.9% (140/242) using at least one prescribed medication (63.6% of players at IBSA 31 
World Games and 57.7% of players at IFCPF World Cup). The most commonly prescribed 32 
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category of medications was non-steroidal anti-inflammatory drugs (NSAIDs), representing 33 
39.3% of all reported medications. 34 
 35 
Conclusion: This study highlights the potential overuse of medication and supplements in 36 
disability football, particularly in the use of NSAIDs. These trends are comparable to 37 
previous research in FIFA World Cup competitions. 38 
 39 
 40 
 41 
 42 
 43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
 51 
 52 
 53 
 54 
 55 
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Introduction 56 
The World Health Organization reports that there are more than 1 billion people world-wide 57 
with a form of impairment, representing over 15% of the world’s population.¹ Individuals 58 
with an impairment can benefit greatly from exercise, particularly team sport, which brings 59 
with it added physical, psychological and social benefits.
2,3
 From a healthcare perspective, 60 
the provision of medical services in disability sport presents many challenges not faced 61 
elsewhere and has been described as “the most challenging and rewarding area of sports 62 
medicine”.
4
 Given the positive impact that sport can have on people with an impairment , it 63 
is vital that measures are taken to better understand the medical issues posed by disability 64 
sport,
5
 to further safeguard athlete welfare. The Football Association created the Centre for 65 
Disability Football Research (FA-CDFR) in England, which shares Fédération Internationale 66 
de Football Association (FIFA) aspirations and commitment to “Football for Health” and 67 
aims to improve the care of athletes with an impairment through medical research in this 68 
field of sports medicine. 69 
 70 
The use of medication has been vital throughout medical history to help prevent and treat 71 
disease. More recently, the legal and prohibited use of medical ingredients has moved into 72 
elite sport to aid recovery from injury and enhance health and performance. It is well 73 
established that medications, in particular non-steroidal anti-inflammatory drugs (NSAIDs), 74 
are over-used in sport.
6-21
 Concerns have been raised about the legal use of prescribed 75 
medications in sport and the potential drug-related adverse effects this may pose to 76 
athletes. A variety of medicines are permitted for athlete use to cure illness, treat injury and 77 
obtain a competitive edge
6
. 78 
 79 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
4 
 
At the Sydney Olympic Games 78% of athletes used medication or supplements, with five 80 
athletes using more than 18 substances in a single day.
6
 In a similar study of Olympic 81 
athletes outside of competition, 40.6% of elite Serbian athletes were reported to be taking 82 
medications, totalling 1.98 medications per athletes.
8
 This study also found significantly 83 
higher rates of medication use in team sports rather than individual events (3.64 vs. 2.63 84 
medications per user, p <0.01). A study of Finnish Olympic athletes
9
 compared medication 85 
use in their cohort against a representative age-matched sample found that athletes use 86 
significantly more medications than controls (74.4% vs. 56.4%, p <0.001, OR 2.30). At the 87 
Athens Paralympic Games 2004, 64.2% of athletes declared use of medication or food 88 
supplement, with NSAIDs (9.8%) and other analgesia (5.6%) being most commonly used 89 
medication
10
. In this study the overall incidence of medication use per athlete was lower in 90 
Paralympic athletes than their Olympic counterparts and fewer individual Paralympic 91 
athletes used a high number of medications when compared to individual Olympic 92 
athletes
10
. In contrast with these findings, a later study with direct comparison of 93 
medication use in Paralympic and Olympic athletes
11
 concluded that the use of physician-94 
prescribed medication, especially those used to treat chronic disease, is higher in Paralympic 95 
athletes than Olympic athletes with the exception of asthma medicines. 96 
 97 
The Fédération Internationale de Football Association Medical Assessment and Research 98 
Centre (F-MARC) have been systematically monitoring and recording the use of medication 99 
and nutritional supplements in international football since the 1998 FIFA World Cup.
16,18,20
 100 
Table 1 demonstrates the results of research on the use of medications in FIFA World Cups. 101 
The most frequently prescribed category of medication during FIFA tournaments was 102 
NSAIDs, representing 36% of all substances used. The results of the published data on 103 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
5 
 
medication use in elite football has greatly concerned FIFA, with the conclusion that “the 104 
high intake of medications in international football - especially of NSAIDs - is alarming and 105 
should be addressed”.
20 106 
 107 
The use of nutritional supplements among elite athletes is well documented with studies 108 
reporting that 45%-81.9% of Olympic athletes use dietary supplements.
6-7,12-13 
At the Athens 109 
Paralympic Games 2004, 42.1% of athletes used food supplements with vitamins (43.5%), 110 
minerals (16.1%) and proteins (10.5%) being most popular
-11
. A comparison of the 111 
prevalence of supplement use in FIFA World Cups
29
 is summarised in Table 2 and suggests 112 
supplement use in elite football is less prevalent than in Olympic sports. The use of 113 
supplements for immunological and nutritional reasons has been declared as unnecessary in 114 
athletes with an adequate diet and when using supplements, it is important to consider the 115 
chance of contamination
22,23
 and the potential for adverse side-effects.
24-26
 The regulations 116 
governing the purity of dietary supplements are not always as stringent as the 117 
pharmaceutical production of clinical drugs, which could result in contamination leading to 118 
the potential of a failed doping test and a subsequent ban from sport.
27,28
 119 
 120 
In the current medical literature, there are no studies investigating the use of medications 121 
and supplements in elite disability football. By analysing the use of medications and 122 
supplements in disability football, the medical profession will begin to learn more about 123 
athlete medical needs, tournament medical planning and medical management of these 124 
athletes. This would potentially reduce the risk of iatrogenic side effects, showing better 125 
consideration of the risk-benefit profile of substance use in athletes and improve athlete 126 
welfare. 127 
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 128 
The aim of this study is to determine and quantitatively describe the use of medication and 129 
supplements in disability football during elite international tournaments, and to identify the 130 
profile of substances used by category. This will generate new knowledge and advance 131 
understanding within disability football medicine. 132 
 133 
 134 
 135 
 136 
 137 
 138 
 139 
 140 
 141 
 142 
 143 
 144 
 145 
 146 
 147 
 148 
 149 
 150 
 151 
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Methods 152 
Study Design 153 
A prospective, cohort study was performed investigating the use of medication and 154 
supplements in elite disability football. 155 
 156 
Data Collection 157 
The methodology chosen was analogous to that used by F-MARC,
16,20
 in similar studies at 158 
FIFA World Cups. In connection with the medical provision for the International Federation 159 
of Cerebral Palsy Football (IFCPF) World Cup 2015 and the International Blind Sports 160 
Association (IBSA) World Games 2015 Football Tournament, a designated member of each 161 
nation’s medical team were asked to enter, in English, any medications or supplements 162 
taken by the players or administered to them in the 48 hours preceding a match on a data 163 
collection sheet (Appendix 1). One person per team was asked to record all data to avoid 164 
duplication of results. The assigned individual was the national team doctor unless the team 165 
did not have a doctor on their staff, in which case the data was collected by the team 166 
physiotherapist. All data was entered in English and where English language skill was limited 167 
the official team liaison officer for the nation, who was bi-lingual with English and the 168 
mother tongue of the nation, supported the designated medical professional with 169 
translation. In the previous research during FIFA World Cups
16,20
 the data was collected for 170 
any substance taken 72 hours before each match, however this was adapted due to the 171 
period between matches being shorter than 72 hours in disability football. The designated 172 
team medical personnel were educated in regards to the project through a presentation on 173 
the research proposal at the tournament medical meeting and via a written information 174 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
8 
 
sheet (Appendix 2). Ethical approval was granted by the University College London Ethics 175 
Committee (Project ID - 6247/001). 176 
 177 
Participating Players 178 
The IFCPF World Cup 2015 at St. George’s Park in England, consisted of 15 national teams 179 
with each country having a squad of 13 or 14 athletes. The IBSA World Games 2015 Football 180 
Tournament in Seoul, South Korea, consisted of 9 national teams with each country having a 181 
squad of 9 or 10 athletes. This equated to 242 athletes eligible for inclusion in the study, 182 
with our data collection covering a total of 826 player-matches. 183 
 184 
The IFCPF World Cup involves athletes with cerebral palsy (CP) who have ataxia, hypertonia 185 
or athetosis, causing a permanent and verifiable activity limitation. CP football uses a 186 
classification system, which groups athletes depending on how their impairment impacts 187 
performance, and CP football includes 4 classes, called FT5, FT6, FT7 and FT8. As CP football 188 
is a team (7-a-side) sport, classification aims at ensuring fairness in regards to the impact of 189 
impairment between both teams. 190 
 191 
The IBSA World Games Football Tournament involves athletes who have a visual impairment 192 
classed as B1, B2 or B3, participating in 5-a-side football matches. Our cohort included 193 
athletes classified as B1, which is defined as visual acuity poorer than LogMAR 2.6, and is the 194 
only visual impairment classification at Paralympic Games. Our study did not include B2/B3 195 
athletes which are classifications of visual impairment but who do not participate in 196 
Paralympics. Visual impairment can arise from a variety of conditions, including genetics, 197 
prenatal developmental differences or from illness or trauma. 198 
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 199 
Substance Classification 200 
The active pharmaceutical ingredient of each substance was identified to categorise the 201 
medication or supplement into one of the following: Analgesia and anti-inflammatory 202 
medications (NSAIDs, other analgesia, local anaesthetics), muscle relaxants, respiratory 203 
agents, gastrointestinal medications, antimicrobial medications, antihistamines, 204 
supplements and others. This classification is consistent with previous pharmaco-205 
epidemiological studies in sport.
6-21
 206 
 207 
Data Presentation 208 
The primary outcome measure of interest was the incidence of substance consumption. This 209 
was determined by calculating: (i) The number of individual athletes reported to be using a 210 
substance per tournament; (ii) Mean substance use/player/match; (iii) Mean substance 211 
use/player/tournament. The proportion (%) of each type of medication, by classification, 212 
was also monitored and analysed. 213 
 214 
Statistical Analysis 215 
The statistical approaches applied were frequency analysis, cross-tabulations and Pearson’s 216 
correlations. Chi-square (χ
2
) tests were used for analysis of substance categories. Mean 217 
values and 95% confidence intervals were calculated using SPSS 22.0 (SPSS Inc. Chicago, IL, 218 
USA). A p-value of <.05 was accepted as statistically significant. 219 
 220 
 221 
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 222 
 223 
Results 224 
At the two disability world championships (IBSA World Games 2015 Football Tournament 225 
and IFCPF World Cup 2015) we studied 242 male, elite international disability football 226 
players, with an age range from 17 to 43 (mean age = 26.02 ± 5.14 years). 227 
 228 
A total intake of 1648 substances (medication or supplement) was reported, of which more 229 
than half (53.1%) were classified as supplements. There were a wide range of medications 230 
prescribed with the most commonly used categories being NSAIDs (39.3%), “other 231 
analgesia” (14.7%) and antihistamines (12.7%), as seen in Figure 1. 232 
 233 
During the two tournaments, the incidence of substance use was 1.26 substances (0.59 234 
medications) per player per match, with the highest substance use in an individual athlete 235 
being 8 substances (6 medications) per match. Four national teams, all of which were 236 
participating in the IFCPF World Cup, gave NSAIDs to every player before every match of the 237 
tournament. Seventy percent (170/242) of players reported using at least one substance per 238 
tournament with 57.9% (140/242) using at least one medication per tournament (63.6% of 239 
players at IBSA World Games and 57.7% of players at IFCPF World Cup), see Table 3. Twenty 240 
nine percent of players reported no medication or supplement use during their respective 241 
tournament. 242 
 243 
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Significantly fewer medications and supplements were taken by blind footballers at the IBSA 244 
World Games 2015 Football Tournament than in footballers with cerebral palsy at the IFCPF 245 
World Cup 2015 (4.67 vs. 7.46 substances/player/tournament, p = .003). 246 
 247 
Non-Steroidal Anti-Inflammatory Drugs and Analgesia 248 
NSAIDs were the most frequently prescribed group of medications, representing 39.3% of all 249 
reported medications (Figure 1). 38% (n = 92) of players took a NSAID at least once during 250 
the tournament, with 18 players using a NSAID before every match, independent of whether 251 
they played or not. Substantial differences were observed between the various national 252 
teams with two clinicians giving NSAIDs to every player before every match, where as 253 
another team did not report using a NSAID during the entire tournament. Ten players 254 
reported using more than one preparation of NSAID at the same time, often by combing 255 
NSAIDs via the oral and topical routes. There was no statistical difference between the use 256 
of NSAIDs at the IBSA World Games 2015 Football Tournament and at the IFCPF World Cup 257 
2015. 258 
 259 
Other analgesia accounted for 14.7% of all medications used at the tournament. Of these 260 
92% were Paracetamol, but Codeine and Tramadol were also used on occasion. There were 261 
only three instances of use of local anaesthetic or corticosteroid injections in this cohort. 262 
 263 
Antihistamines 264 
Antihistamines were the second most commonly prescribed category of medication (98 out 265 
of 773 medications) with all of these being prescribed and taken at the IFCPF World Cup 266 
2015. In 61 out of the 98 (62.2%) instances of antihistamine use they were taken via the oral 267 
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route. The remaining cases used topical antihistamine (30/98), intraocular antihistamine 268 
(6/98) and in one instance an IV dose of Chloranphenamine was given for anaphylaxis. 269 
 270 
Medications for the Respiratory Tract 271 
Within this cohort, 10 athletes (4.1%) had diagnosed asthma or exercise-induced 272 
bronchospasm and therefore used respiratory medications. We recorded 84 respiratory 273 
drugs being used before matches over the tournament, which represented 5.1% of all 274 
substances used and 10.9% of all medications used. As one would expect, the majority of 275 
these were inhaled β2-agonist (n = 66, 78.6%) and inhaled corticosteroids (n=14, 16.7%). 276 
 277 
Supplements 278 
Supplements represented a large volume (875/1648, 53.1%) of the substances taken during 279 
the tournaments. Vitamins were the most commonly used supplement (420/1648, 48%), 280 
followed by minerals (289/1648, 33%) and creatine (157/1648, 18%). 281 
 282 
Five teams used multivitamins on every player in their squad before every match in the 283 
tournament and some athletes were identified to take up to 6 different supplements before 284 
a match. 285 
 286 
Relationships with Player Exposure and Team Success 287 
At both tournaments, there was no significant correlation between the number of matches 288 
played by each player and the total substances used, total medications used or total NSAIDs 289 
used. There was no statistically significant correlation between the success of the team 290 
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(measured by final ranking) in the tournament and the mean number of substances used 291 
per player. 292 
 293 
 294 
 295 
Discussion 296 
This is the first study investigating medication and supplement use in elite disability football, 297 
in comparison to prior studies which looked at either a country-specific cohort
11
 and/or a 298 
cohort of all athletes at a Paralympic Games
10
. The results from the present study indicate 299 
the widespread use of medications and supplements at two disability football world cups. In 300 
total, we recorded the use of 1648 substances for 242 players, playing an average of 3.18 301 
matches each. More than half (53.1%) were classified as supplements, with a rate of 1.26 302 
substances (0.59 medications) per player per match. This trend is slightly lower than seen in 303 
previous research in football28 at FIFA World Cups, where male footballers have a rate of 304 
0.77 medications per player per match and female footballers report a rate of 0.85 305 
medications per player per match. The results are, however, comparable to the rate of 306 
medication use in the U-20 and U-17 FIFA World Cups, where players are reported to use 307 
0.51 medications per player per match. The number and proportion of disability footballers 308 
using medications is however much higher than in footballers participating in FIFA World 309 
Cups, with our study finding 57.9% of players using at least one medication per tournament, 310 
compared to 48.2% of elite male footballers17 and 37.9% of elite female and youth 311 
footballers.16 This trend might reflect the possibility that athletes with an impairment have a 312 
higher rate of injury than able-bodied athletes29-31 or may be due to these athletes being 313 
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more commonly prescribed regular medications to manage chronic medical conditions. Do 314 
disability footballers have more co-morbidities and so require regular medications? Do they 315 
suffer more overuse injuries because of their disability and subsequent biomechanical 316 
differences? Do athletes with an impairment have altered pain perception resulting in 317 
increasing analgesic requirements? These questions, and many more, are all relevant to this 318 
study and remain unanswered but are potential targets for future research in the field of 319 
disability sport. 320 
 321 
Non-Steroidal Anti-Inflammatory Drugs 322 
Previous research in able-bodied athletes has revealed high and unexpected levels of 323 
medication use especially of NSAIDs.6-19 In keeping with much of this research, NSAIDs were 324 
by far the most commonly used medication in disability footballers in our cohort, 325 
representing 39.3% of all medications used. Over one third (n = 92, 38%) of all players took a 326 
NSAID at least once during the tournament, with 18 players (7.4%) using a NSAID before 327 
every match, and with 6 players (2.5%) using two or more different preparations of NSAID 328 
concurrently. The findings are lower than the 54.5% of male players, 50.9% of female 329 
players and 43.4% of adolescent players using NSAIDs at FIFA World Cups.32 As suggested in 330 
previous studies our findings on use of NSAIDs in sport are alarming and go against current 331 
guidelines,33,34 which recommend using the lowest possible dose and for shortest possible 332 
period and using one preparation of NSAID at a time. Of particular concern was the fact that 333 
one national team used topical NSAIDs on every player before every match, independent of 334 
whether the player was starting a match or was a substitute. 335 
 336 
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One possible explanation for the high rate of NSAID use is the readiness of doctors, 337 
physiotherapists, coaches and players to use this class of medication prophylactically to 338 
mask pain and allow continuation in sport, rather than to treat injury, but this practice 339 
needs to change to reduce the potential iatrogenic side-effects of NSAIDs. Endurance 340 
athletes who use NSAIDs have an almost five times higher incidence of adverse events.35,36 341 
NSAID-associated gastrointestinal adverse events and changes in renal function and 342 
nephritis have been reported in athletes taking NSAIDs during exercise.37,38 NSAIDs can also 343 
have a negative effect on bone turnover and osteoblast activity39,40 and this is particularly 344 
important in our cohort as CP is associated with osteoporosis and osteopenia.41,42 The 345 
clinical use of NSAIDs should therefore be balanced between the potential benefits and side 346 
effects and should follow clinical guidelines. 347 
 348 
The risks associated with NSAIDs35-40 can be reduced by using alternative analgesia, such as 349 
Paracetamol, which has a similar analgesic success.43 Despite this fact, alternative analgesia, 350 
mainly (92%) composing of Paracetamol, only represented 14.7% of all medications used at 351 
the disability football world cups. Therefore, where analgesia is required, one potential 352 
target to reduce NSAID-associated risks is to try to manage pain by using Paracetamol rather 353 
than NSAIDs. 354 
 355 
Antihistamines 356 
The relatively high use of antihistamines at the IFCPF World Cup is likely to reflect the fact 357 
that the tournament took place in summer, with high pollen counts affecting the local 358 
environment in the UK at this time of year. 359 
 360 
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Supplements 361 
The use of supplements in disability football is relatively common, with 53.1% of the 362 
substances used at the tournaments being classed as supplements, and with 30.2% of all 363 
players taking at least one supplement during the tournaments. These figures compare 364 
closely to the supplement use in FIFA World Cups, where 33.4% of male footballers and 365 
45.6% of female footballers use supplements. The trends are, however, lower than the 366 
documented use of supplements in Olympic athletes, which ranges from 45% - 81.9%.6-9 The 367 
use of supplements, for immunological and nutritional reasons, is often unnecessary in 368 
athletes with an ‘adequate’ diet and when using supplements it is important to consider the 369 
chance of contamination22,23 and the potential for adverse side-effects.23-25 The findings of 370 
this study suggest that supplements are not overused in disability football when compared 371 
to other forms of football or other sports. 372 
 373 
Limitations to the study 374 
Within this study there are various limitations which need to be considered when analysing 375 
the data and ahead of further research in this field. The data in the study comes directly 376 
from official team clinicians on their prescribing patterns with the involvement of players, 377 
but data was not taken from players themselves, which may raise an issue with 378 
concordance. Self-medicating athletes who did not disclose the use of certain substances 379 
were not included in our data set because their data could not be recorded or accounted 380 
for, which could underestimate the true prevalence of medication use. The information 381 
reported was also not verified by blood analysis so could not be objectively confirmed. 382 
Another aspect to consider is that in studies taking data from team physicians, the use of 383 
regular medications might have been excluded by the clinician because they did not actually 384 
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prescribe those medications, which might further underestimate the true use of 385 
medications in athletes. Also, whilst this study looked at the prevalence of substance use 386 
and the types of medications and supplements used, it did not investigate the underlying 387 
reasons for this current practice. Accurate medication recall is very important to the validity 388 
of pharmaco-epidemiological studies and therefore this study endeavoured to account for 389 
this by asking clinicians to promptly record in a written manner substance given, but 390 
unfortunately this aspect of monitoring substance use cannot be fully controlled. 391 
 392 
Conclusions 393 
The present study highlights the problems with overuse of medication in elite disability 394 
football and indicates that the current use of NSAIDs in disability football is high but is 395 
slightly lower than the “over-use”16,18 seen in professional football. It also suggests the use 396 
of supplements is comparable to that seen in FIFA World Cups. This study highlights the 397 
need for more research to establish the injury and illness patterns in disability sport to 398 
better link the use of medical substances, and to understand the reasons as to why athletes 399 
use medications and supplements. F-MARC have campaigned to reduce the use of NSAIDs in 400 
professional football and have initiated an education programme for clinicians, but more 401 
work is needed to spread this message within disability football. 402 
 403 
 404 
 405 
 406 
 407 
 408 
 409 
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Tables and Figures 442 
 443 
Table 1 - Medication Use at FIFA World Cups 444 
 445 
 446 
Tournament Teams Players Matches Reports 
Medications 
Prescribed 
Intake of Medication 
(per player, per match) 
FIFA World Cup 2014 32 736 64 2944 2346 0.80 
FIFA World Cup 2010 32 736 64 2944 2335 0.79 
FIFA World Cup 2006 32 736 64 2944 2052 0.70 
FIFA World Cup 2002 32 736 64 2944 2392 0.81 
FIFA Women’s WC 2007 16 336 32 1344 1200 0.89 
FIFA Women’s WC 2003 16 320 32 1280 1036 0.81 
FIFA U-20 World Cup 2007 24 504 52 2184 965 0.44 
FIFA U-20 World Cup 2005 24 504 52 2184 1248 0.57 
FIFA U-17 World Cup 2007 24 504 52 2184 1036 0.47 
FIFA U-17 World Cup 2005 16 320 32 1280 717 0.56 
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Table 2 - Supplement Use at FIFA World Cups
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 448 
 449 
 450 
 451 
 452 
 453 
Table 3 - Number of Players using Each Medication Category during Tournament 454 
Tournament 
Supplement per Match 
N (%) 
Supplement per Tournament 
N (%) 
FIFA World Cups 2002-2014 2985 (25.3%) 984 (33.4%) 
FIFA Women’s World Cups 2003-2007 880 (33.5%) 229 (45.6%) 
FIFA U-20 & U-17 World Cups 2005-2007 3104 (39.6%) 906 (49.5%) 
Medication Category 
IBSA World Games 2015 
Football Tournament 
IFCPF World 
Cup 2015 
No. of players 
(n = 48) 
% of players 
No. of players 
(n = 194) 
% of players 
Any Medication 28 63.6% 112 57.7% 
NSAIDs 19 39.6% 73 37.6% 
Other Analgesia 19 39.6% 37 19.1% 
Injections 2 4.2% 1 0.5% 
Respiratory Drugs 4 8.3% 8 4.1% 
Gastrointestinal Agents 2 4.2% 9 4.6% 
Antimicrobials 1 2.1% 10 5.2% 
Antihistamines 0 0% 18 9.3% 
Any Supplement 12 25% 61 31.4% 
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Figure 1 - Substances Used by Category 456 
Appendix 1 457 
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Medication Use Report Form 
 
 
Player Initials:    Team:       Date:     
 
Name of Medication or active 
pharmaceutical indigence  
Drug Code 
see below 
Daily Frequency & 
Dose 
Route Duration  Indication 
        x                mg  Oral / IM / IV / Topical / Inhaled          Days  
 
 
       x                mg  Oral / IM / IV / Topical / Inhaled          Days  
 
 
       x                mg  Oral / IM / IV / Topical / Inhaled          Days  
 
 
       x                mg  Oral / IM / IV / Topical / Inhaled          Days  
 
 
       x                mg  Oral / IM / IV / Topical / Inhaled          Days  
 
 
       x                mg  Oral / IM / IV / Topical / Inhaled          Days  
 
 
       x                mg  Oral / IM / IV / Topical / Inhaled          Days  
 
 
       x                mg  Oral / IM / IV / Topical / Inhaled          Days  
 
 
       x                mg  Oral / IM / IV / Topical / Inhaled          Days  
 
Drug Code:  
1 = NSAIDs 4 = Muscle Relaxants 7 = Antimicrobials 
2 = Other Analgesia 5 = Respiratory Drugs 8 = Supplements 
3 = Injected Corticosteroids 6 = Medication for Gastrointestinal 9 = Antihistamine 
      & Local Anaesthetics       Purpose 10 = Others 
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